Phenotypic, genotypic, and functional characterization of normal and acute myeloid leukemia-derived marrow endothelial cells

Experimental Hematology

Volumn 44, Issue 5, 2016, Pages 378-389

  Pizzo, Russell J ^a   Azadniv, Mitra ^a   Guo, Naxin ^a   Acklin, Joshua ^a   Lacagnina, Kimberly ^a   Coppage, Myra ^a   Liesveld, Jane L ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL LOW DENSITY LIPOPROTEIN; ANGIOPOIETIN RECEPTOR; CD31 ANTIGEN; CXCL16 CHEMOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN C FOS; VASCULOTROPIN; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; VASCULOTROPIN A;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL ADHESION; CELL CULTURE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; TUMOR MICROENVIRONMENT; UPREGULATION; BONE MARROW CELL; CELL LINE; CELL LINEAGE; GENE EXPRESSION PROFILING; GENETICS; HL 60 CELL LINE; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL CULTURE; TUMOR CELL LINE; U937 CELL LINE;

ANTIGENS, CD; ANTIGENS, CD31; BONE MARROW CELLS; CELL LINE; CELL LINE, TUMOR; CELL LINEAGE; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; GENOTYPE; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE; RECEPTOR, TIE-2; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; U937 CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84962480132     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2016.01.008     Document Type: Article

References (52)

1. Juliusson G., Antunovic P., Derolf A., et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113:4179-4187.
2. Chen Y., Jacamo R., Shi Y.X., et al. Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood 2012, 119:4971-4980.
3. Lane S.W., Scadden D.T., Gilliland D.G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009, 114:1150-1157.
4. Rafii S., Mohle R., Shapiro F., Frey B.M., Moore M.A. Regulation of hematopoiesis by microvascular endothelium. Leuk Lymphoma 1997, 27:375-386.
5. Garrido S.M., Appelbaum F.R., Willman C.L., Banker D.E. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001, 29:448-457.
6. Glenjen N.I., Hatfield K., Bruserud O. Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels. Eur J Haematol 2005, 74:24-34.
7. Liesveld J.L., Rosell K.E., Lu C., et al. Acute myelogenous leukemia-Microenvironment interactions: role of endothelial cells and proteasome inhibition. Hematology 2005, 10:483-494.
8. Hussong J.W., Rodgers G.M., Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000, 95:309-313.
9. Wierzbowska A., Robak T., Krawczynska A., et al. Circulating endothelial cells in patients with acute myeloid leukemia. Eur J Haematol 2005, 75:492-497.
10. Fiedler W., Graeven U., Ergun S., et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997, 89:1870-1875.
11. Hatfield K.J., Hovland R., Oyan A.M., et al. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 2008, 22:287-293.
12. Reikvam H., Hatfield K.J., Lassalle P., Kittang A.O., Ersvaer E., Bruserud O. Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert Opin Investig Drugs 2010, 19:169-183.
13. Schliemann C., Bieker R., Padro T., et al. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 2006, 91:1203-1211.
14. Colmone A., Amorim M., Pontier A.L., Wang S., Jablonski E., Sipkins D.A. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008, 322:1861-1865.
15. Kfoury Y., Scadden D.T. Cellular thrust and parry in the leukemic niche. Blood 2014, 124:2760-2761.
16. Costa L.F., Balcells M., Edelman E.R., Nadler L.M., Cardoso A.A. Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB. Blood 2006, 107:285-292.
17. Parmar K., Mauch P., Vergilio J.A., Sackstein R., Down J.D. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007, 104:5431-5436.
18. Braut-Boucher F., Pichon J., Rat P., Adolphe M., Aubery M., Font J. A non-isotopic, highly sensitive, fluorimetric, cell-cell adhesion microplate assay using calcein AM-labeled lymphocytes. J Immunol Methods 1995, 178:41-51.
19. Liesveld J.L., Bechelli J., Rosell K., et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res 2007, 31:1553-1563.
20. Trapnell C., Hendrickson D.G., Sauvageau M., Goff L., Rinn J.L., Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol 2013, 31:46-53.
21. Netland P.A., Zetter B.R., Via D.P., Voyta J.C. In situ labelling of vascular endothelium with fluorescent acetylated low density lipoprotein. Histochem J 1985, 17:1309-1320.
22. Suda T., Dexter T.M. Effect of hydrocortisone on long-term human marrow cultures. Br J Haematol 1981, 48:661-664.
23. Krones-Herzig A., Mittal S., Yule K., et al. Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. Cancer Res 2005, 65:5133-5143.
24. Rafii S., Shapiro F., Rimarachin J., et al. Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. Blood 1994, 84:10-19.
25. Ema H., Suda T. Two anatomically distinct niches regulate stem cell activity. Blood 2012, 120:2174-2181.
26. Civini S., Jin P., Ren J., et al. Leukemia cells induce changes in human bone marrow stromal cells. J Transl Med 2013, 11:298.
27. Hatfield K., Oyan A.M., Ersvaer E., et al. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br J Haematol 2009, 144:53-68.
28. Pezeshkian B., Donnelly C., Tamburo K., Geddes T., Madlambayan G.J. Leukemia mediated endothelial cell activation modulates leukemia cell susceptibility to chemotherapy through a positive feedback loop mechanism. PLoS One 2013, 8:e60823.
29. Poulos M.G., Gars E.J., Gutkin M.C., et al. Activation of the vascular niche supports leukemic progression and resistance to chemotherapy. Exp Hematol 2014, 42:976-986. e971-e973.
30. Stucki A., Rivier A.S., Gikic M., Monai N., Schapira M., Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001, 97:2121-2129.
31. Veiga J.P., Costa L.F., Sallan S.E., Nadler L.M., Cardoso A.A. Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival. Exp Hematol 2006, 34:610-621.
32. Duan C.W., Shi J., Chen J., et al. Leukemia propagating cells rebuild an evolving niche in response to therapy. Cancer Cell 2014, 25:778-793.
33. Reikvam H., Nepstad I., Bruserud O., Hatfield K.J. Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. Oncotarget 2013, 4:830-843.
34. Zhang J., Ye J., Ma D., et al. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway. Carcinogenesis 2013, 34:667-677.
35. Kim J.A., Shim J.S., Lee G.Y., et al. Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia. Cancer Res 2015, 75:2222-2231.
36. Umezu T., Ohyashiki K., Kuroda M., Ohyashiki J.H. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene 2013, 32:2747-2755.
37. Cogle C.R., Goldman D.C., Madlambayan G.J., et al. Functional integration of acute myeloid leukemia into the vascular niche. Leukemia 2014, 28:1978-1987.
38. Zeng Z., Shi Y.X., Samudio I.J., et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009, 113:6215-6224.
39. Wang Y.Z., Cao M.L., Liu Y.W., He Y.Q., Yang C.X., Gao F. CD44 mediates oligosaccharides of hyaluronan-induced proliferation, tube formation and signal transduction in endothelial cells. Exp Biol Med (Maywood) 2011, 236:84-90.
40. Isozaki T., Arbab A.S., Haas C.S., et al. Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis: studies in mice with K/BxN serum-induced arthritis. Arthritis Rheum 2013, 65:1736-1746.
41. Ria R., Todoerti K., Berardi S., et al. Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clin Cancer Res 2009, 15:5369-5378.
42. Jacamo R., Chen Y., Wang Z., et al. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-kappaB mediates chemoresistance. Blood 2014, 123:2691-2702.
43. Blau O., Baldus C.D., Hofmann W.K., et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 2011, 118:5583-5592.
44. Zahiragic L., Schliemann C., Bieker R., et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 2007, 21:1310-1312.
45. Trujillo A., McGee C., Cogle C.R. Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J Oncol 2012, 2012:128608.
46. Madlambayan G.J., Meacham A.M., Hosaka K., et al. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 2010, 116:1539-1547.
47. Benezra M., Phillips E., Tilki D., et al. Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent. Leukemia 2012, 26:1771-1778.
48. Hsieh Y.T., Gang E.J., Geng H., et al. Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood 2013, 121:1814-1818.
49. Oellerich T., Oellerich M.F., Engelke M., et al. β2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis. Blood 2013, 121:3889-3899. S1-66.
50. Zarbock A., Kempf T., Wollert K.C., Vestweber D. Leukocyte integrin activation and deactivation: novel mechanisms of balancing inflammation. J Mol Med 2012, 90:353-359.
51. Boyd A.L., Campbell C.J., Hopkins C.I., et al. Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs. J Exp Med 2014, 211:1925-1935.
52. Kvestad H., Evensen L., Lorens J.B., Bruserud O., Hatfield K.J. In vitro characterization of valproic acid, ATRA, and cytarabine used for disease-stabilization in human acute myeloid leukemia: antiproliferative effects of drugs on endothelial and osteoblastic cells and altered release of angioregulatory mediators by endothelial cells. Leuk Res Treatment 2014, 2014:143479.